Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRDd With or Without ASCT in Newly Diagnosed Multiple Myeloma
NCT04288765Phase 3Withdrawn
- Sponsor
- PETHEMA
- Start
- Mar 2020
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of daratumumab in multiple myeloma (MM), sponsored by PETHEMA. Planned start Mar 2020; status: withdrawn.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04288765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04288765.